TradeFlare's AI research teams analysed EDIT on 11 market nights between April 28, 2026 and July 8, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 8, 2026 | HOLD | $3.75 | — / — | -17.2% | -25.1% | Post-earnings drift signal from scanner. |
| July 7, 2026 | HOLD | $3.65 | — / — | -15.7% | -26.1% | Post-earnings drift signal from scanner. |
| July 6, 2026 | HOLD | $3.65 | — / — | -13.4% | -27.4% | Post-earnings drift signal from scanner. |
| July 3, 2026 | BUY | $3.65 | — / — | -13.4% | -27.4% | Post-earnings drift signal from scanner. |
| May 15, 2026 | HOLD | $2.85 | — / — | +5.3% | -6.1% | No clear bullish catalyst identified in the current market regime. |
| May 14, 2026 | HOLD | $2.90 | — / — | -6.3% | -12.3% | Significant positive clinical trial data for a lead program. |
| May 5, 2026 | HOLD | $3.00 | $3.60 / $2.55 | -3.6% | -8.6% | The current market regime is neutral, and the stock exhibits conflicting technical signals and weak fundamentals, necessitating a wait for a clearer catalyst or improved risk/reward. |
| May 4, 2026 | BUY | $2.90 | — / — | +2.0% | -6.0% | No clear bullish catalysts identified. |
| April 30, 2026 | BUY | $2.82 | — / — | +1.0% | +15.3% | Positive clinical trial data for gene-editing therapies. |
| April 29, 2026 | HOLD | $3.06 | — / — | +12.6% | +21.6% | |
| April 28, 2026 | BUY | $2.89 | — / — | -0.7% | +16.7% | No clear bullish catalysts identified. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.